Literature DB >> 22936369

Genetics and metabolic cardiomyopathies.

E C Wicks1, P M Elliott.   

Abstract

Metabolic disorders encompass a heterogeneous group of conditions that commonly affect the heart and contribute adversely to cardiovascular outcomes. As the heart is a metabolically active organ, inborn errors in metabolism (IEMs) often present with cardiac manifestations such as cardiomyopathy, arrhythmia, and valvular dysfunction. More than 40 IEMs are reported to cause cardiomyopathy, including fatty acid oxidation defects, glycogen, lysosomal and perioxisome storage diseases, mitochondrial cardiomyopathies, organic acidaemias, aminoacidopathies and congenital disorders of glycosylation. Studies suggest that IEM account for only 5% of cardiomyopathies; however, their diagnosis is imperative to enable the effective institution of disease-specific management strategies. This review describes the more common genetic defects that affect metabolic pathways and give rise to heart muscle disease.

Entities:  

Mesh:

Year:  2012        PMID: 22936369     DOI: 10.1007/s00059-012-3659-0

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  66 in total

1.  Severe valvular and aortic arch calcification in a patient with Gaucher's disease homozygous for the D409H mutation.

Authors:  R George; J McMahon; B Lytle; B Clark; A Lichtin
Journal:  Clin Genet       Date:  2001-05       Impact factor: 4.438

2.  Carnitine membrane transporter deficiency: a long-term follow up and OCTN2 mutation in the first documented case of primary carnitine deficiency.

Authors:  Stephen D Cederbaum; Samantha Koo-McCoy; Ingrid Tein; Betty Y L Hsu; Arupa Ganguly; Eric Vilain; Katrina Dipple; Ljerka Cvitanovic-Sojat; Charles Stanley
Journal:  Mol Genet Metab       Date:  2002-11       Impact factor: 4.797

3.  Lysosomal glycogen storage disease with normal acid maltase.

Authors:  M J Danon; S J Oh; S DiMauro; J R Manaligod; A Eastwood; S Naidu; L H Schliselfeld
Journal:  Neurology       Date:  1981-01       Impact factor: 9.910

4.  Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history.

Authors:  Ross T Murphy; Jens Mogensen; Kate McGarry; Ajay Bahl; Alison Evans; Eyman Osman; Petros Syrris; Grainne Gorman; Michael Farrell; Janice L Holton; Michael G Hanna; Sian Hughes; Perry M Elliott; Calum A Macrae; William J McKenna
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

5.  Mucopolysaccharidosis I presenting with endocardial fibroelastosis of infancy.

Authors:  M J Stephan; E L Stevens; R J Wenstrup; C R Greenberg; H L Gritter; G F Hodges; B Guller
Journal:  Am J Dis Child       Date:  1989-07

6.  Cardiovascular changes in children with mucopolysaccharide disorders.

Authors:  U R Mohan; A A Hay; M A Cleary; J E Wraith; R G Patel
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299

7.  D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD).

Authors:  Johan L K Van Hove; Stephanie Grünewald; Jaak Jaeken; Philippe Demaerel; Peter E Declercq; Pierre Bourdoux; Klary Niezen-Koning; John E Deanfeld; James V Leonard
Journal:  Lancet       Date:  2003-04-26       Impact factor: 79.321

Review 8.  Carnitine transport: pathophysiology and metabolism of known molecular defects.

Authors:  I Tein
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

9.  Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0.

Authors:  Gittan Kollberg; Már Tulinius; Thomas Gilljam; Ingegerd Ostman-Smith; Gun Forsander; Peter Jotorp; Anders Oldfors; Elisabeth Holme
Journal:  N Engl J Med       Date:  2007-10-11       Impact factor: 91.245

Review 10.  Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects.

Authors:  Jean-Paul Bonnefont; Fatima Djouadi; Carina Prip-Buus; Stephanie Gobin; Arnold Munnich; Jean Bastin
Journal:  Mol Aspects Med       Date:  2004 Oct-Dec
View more
  6 in total

Review 1.  Chromosomal regulation by MeCP2: structural and enzymatic considerations.

Authors:  N J Bowen; M B Palmer; P A Wade
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

2.  [The 2014 ESC guidelines on the diagnosis and management of hypertrophic cardiomyopathy : what is new?].

Authors:  B Maisch; H Mahrholdt
Journal:  Herz       Date:  2014-12       Impact factor: 1.443

3.  Nothing new in heart failure? A current misconception!

Authors:  B Maisch
Journal:  Herz       Date:  2012-12       Impact factor: 1.443

4.  Familial dilated cardiomyopathy. Clinical and genetic characteristics.

Authors:  A Serio; N Narula; T Kodama; V Favalli; E Arbustini
Journal:  Herz       Date:  2012-12       Impact factor: 1.443

Review 5.  Infant with cardiomyopathy: When to suspect inborn errors of metabolism?

Authors:  Stephanie L Byers; Can Ficicioglu
Journal:  World J Cardiol       Date:  2014-11-26

6.  Inappropriate cathepsin K secretion promotes its enzymatic activation driving heart and valve malformation.

Authors:  Po-Nien Lu; Trevor Moreland; Courtney J Christian; Troy C Lund; Richard A Steet; Heather Flanagan-Steet
Journal:  JCI Insight       Date:  2020-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.